IONS Exec Sells $126K in Shares via Pre-Planned 10b5-1 Transaction
IONIS PHARMACEUTICALS INC
Subscribe to track IONS
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
IONS Exec Sells $126K in Shares via Pre-Planned 10b5-1 Transaction
Company: IONIS PHARMACEUTICALS INC (IONS) Form: 4/A | Filed: 2025-11-07 Significance: Low
Insider: Geary Richard S Title: EVP, Chief Development Officer | Relationship: Officer
Transaction: • Type: Sell (following option exercise) • Shares: 1,680 • Price: $75.054 • Value: $126,091 • Owned After: 59,657
Key Insight: This is a routine, pre-scheduled 'exercise-and-sell' transaction under a 10b5-1 plan to cover option costs and lock in compensation. It is not considered a discretionary sale based on new information.
Market Context: The transaction value represents a negligible 0.001% of the company's $12.1B market cap, indicating minimal market impact.
This is PUBLIC SEC data for educational purposes. Not investment advice.
Comprehensive Analysis
SEC Filing Analysis: IONIS PHARMACEUTICALS INC (IONS)
Executive Summary
- Trading Significance: Low
- Key Takeaway: An officer conducted a routine, pre-planned 'exercise-and-sell' transaction valued at approximately $126K under a 10b5-1 plan, indicating it is likely for compensation and tax purposes rather than a change in outlook.
- Market Impact: Negligible, given the transaction's small size relative to the company's market capitalization.
Company Information
| Field | Value |
|---|---|
| Company | IONIS PHARMACEUTICALS INC |
| Ticker Symbol | IONS |
| CIK | 0000874015 |
| Industry | PHARMACEUTICAL PREPARATIONS [2834] |
Insider Information
| Field | Value |
|---|---|
| Name | Geary Richard S |
| CIK | 0001442730 |
| Title/Position | EVP, Chief Development Officer |
| Relationship | Officer |
Transaction Details
This filing reports the exercise of stock options (Code 'M') and the immediate sale of the acquired shares (Code 'S'). The analysis focuses on the open market sale.
| Field | Value |
|---|---|
| Form Type | 4/A |
| Transaction Date | 2025-11-03 |
| Transaction Code | S (Sale) & M (Option Exercise) |
| Security Type | Common Stock |
| Shares Involved | 1,680 |
| Price Per Share | $75.054 (Weighted Avg. Sale Price) |
| Total Value | $126,090.72 (Sale Value) |
| Shares Owned After | 59,657 |
| Ownership Type | Direct |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | $126,090.72 |
| % of Market Cap | 0.001% |
| Shares Transacted | 1,680 |
| % of Shares Outstanding | 0.001% |
| Post-Transaction Ownership | 59,657 shares (0.037% of outstanding) |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: The $126K sale is immaterial against Ionis Pharmaceuticals' $12.10 billion market capitalization.
- Transaction Significance: The transaction represents a tiny fraction of both market cap and shares outstanding, falling far below any threshold for significance. The use of a 10b5-1 plan further reduces its informational value.
Additional Context
Transaction Notes
- Special Circumstances: The transactions were executed under a Rule 10b5-1 trading plan, which was disclosed in the filing. This indicates the trades were pre-scheduled and not based on immediate market sentiment or inside information. This is a common practice for executives to systematically liquidate portions of their equity compensation.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.